Both ADXS and DNDN look good, but buying ADXS now is comparable to buying DNDN in 2009. With a market cap of $30 million, ADXS has incredible upside. Look for February 2013 catalyst as ADXS reports the CIN Phase II trial mid-dose result.
I don't know what or who started all the posts between the ADXS and DNDN boards, but it's escalted into a lot of mindless bashing. I'll just say to anyone interested in learning more about Advaxis go to the company's website and check out the presentation the CEO gave at the MedOne conference last week, which has a lot of good information (as opposed to B.S. people write on these boards). Like DNDN, ADXS has a lot going for it. DNDN is clearly a trailblazer having received the first immunotherapy approval by the FDA. ADXS is working toward FDA approval as well (with four Phase II trials currently in progress - two to be completed this year). As an endorsement of both companies, I find it interesting that in 2012 at the Vaccine Industry Excellence Awards, ADXS was awarded the Best Therepeutic Vaccine (approved or in development) for its HPV construct, while DNDN was awarded the same award for Provenge in 2010. Both companies have a lot going for them, just that ADXS is in a much ealier stage (more risk at this point, but greater upside potential). GLTA